XM does not provide services to residents of the United States of America.
F
F

Fresenius

News

Adyen NV, Beazley, Nel ASA

EUROPE RESEARCH ROUNDUP-Adyen NV, Beazley, Nel ASA Aug 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen NV, Beazley and Nel ASA, on Friday. HIGHLIGHTS * Adyen NV ADYEN.AS : TD Cowen raises target price to EUR 1,620 from EUR 1,618 * Beazley BEZG.L : HSBC raises target price to 780p from 665p * Diageo DGE.L : HSBC cuts target price to 3,000p from 3,300p * Nel ASA NEL.OL : Berenberg cuts to hold from buy * ThyssenKrupp Nucera
A
A
B
B
B
C
C
D
D
E
F
F
G
H
I
L
P
P
S
T
V
D
D
F

Danske Bank, Greggs, HSBC

EUROPE RESEARCH ROUNDUP-Danske Bank, Greggs, HSBC Aug 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Greggs, and HSBC, on Thursday. HIGHLIGHTS * Danske Bank DANSKE.CO : HSBC raises target price to DKK 258 from DKK 257 * Greggs GRG.L : Berenberg raises target price to 3600p from 3340p * HSBC HSBA.L : Berenberg raises target price to 870p from 830p * Kardex Holding AG KARN.S : Berenberg raises target price to CHF 260
A
A
A
A
A
B
B
C
C
C
D
F
G
G
H
L
T
W
A
D
S

Fresenius beats Q2 view on strong unit performance, cost savings

UPDATE 2-Fresenius beats Q2 view on strong unit performance, cost savings Adds details on restructuring in paragraphs 5, 6, profit for units in paragraph 7 By Bartosz Dabrowski July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings.
F
F

Fresenius beats Q2 expectations on strong unit performance, cost savings

Fresenius beats Q2 expectations on strong unit performance, cost savings July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings. It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago.
F
F

Dialysis firm FMC cuts outlook for US treatment volumes, shares fall

UPDATE 1-Dialysis firm FMC cuts outlook for US treatment volumes, shares fall Recasts with US patient volumes outlook, adds shares in paragraph 4 July 30 (Reuters) - World's largest dialysis specialist Fresenius Medical Care FMEG.DE cut the outlook for volumes in its key U.S. market on Tuesday after revenue from treatments there fell in the second quarter, weighed down by elevated mortality due to COVID-19 and flu among its patients.
F
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.